The tumor immune microenvironment shapes response to pembrolizumab in microsatellite instability-high endometrial cancer
Jeffrey How(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Aung Naing(The University of Texas MD Anderson Cancer Center), Linghua Wang(The University of Texas MD Anderson Cancer Center), Minghao Dang(The University of Texas MD Anderson Cancer Center), Weiyi Peng(University of Houston), Karen H. Lu(The University of Texas MD Anderson Cancer Center), Elizabeth D. Euscher(The University of Texas MD Anderson Cancer Center), Shrina Patel(The University of Texas MD Anderson Cancer Center), Patrick Hwu(Moffitt Cancer Center), Melinda S. Yates(University of North Carolina at Chapel Hill)
Cited by 4
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k